ALB and Cirrhosis: Preventing HRS involves employing specific interventions such as albumin use, antibiotics, and nonselective β-blocker therapy, tailored to the severity of cirrhosis. Although lacking FDA approval, terlipressin is validated as the first-line pharmacotherapy for HRS in the US, while bridging strategies like RRT, liver dialysis, and TIPS are considered before orthotopic liver transplantation (OLT) or simultaneous liver-kidney transplant (SLK) for definitive treatment.